QUOTE AND NEWS
Benzinga  Dec 12  Comment 
Analysts at Morgan Stanley downgraded Mindray Medical International (NYSE: MR) from Equal-weight to Underweight. The price target for Mindray Medical has been lowered from $37 to $28. Mindray Medical shares have declined 24.02% over the past...
Benzinga  Dec 12  Comment 
newratings.com  Nov 4  Comment 
BEIJING (dpa-AFX) - Mindray Medical International Limited (MR) Monday reported third-quarter net income of $46.0 million or $0.39 per share, up from $30.1 million or $0.25 per share last year. Net revenues rose to $324.6 million from $296.3...
Market Intelligence Center  Oct 28  Comment 
After closing Monday at $29.28, Mindray Medical International Ltd (MR) presents an attractive opportunity to get a 9.37% return in just 171 days, which is an annualized return of 20% (for comparison purposes only). To enter this trade, sell one...
Market Intelligence Center  Oct 15  Comment 
MarketIntelligenceCenter.com's option-trade picking algorithms have identified an attractive covered-call trade on Mindray Medical International Ltd (MR). Look at the Jan. '15 $30.00 covered call for a net debit in the $28.13 area. This trade has...
Market Intelligence Center  Aug 20  Comment 
After Tuesday’s trading in Mindray Medical International Ltd (MR) the option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center uncovered a trade that offers a 12.61% return, or 30.69% annualized...
SeekingAlpha  Aug 12  Comment 
Mindray Medical International Ltd. (NYSE:MR) Q2 2014 Earnings Conference Call August 12, 2014 8:00 ET Executives Cathy Gao – Senior Manager of Investor Relations Li Xiting – President and the Co-CEO Minghe Cheng – Co-CEO...
Benzinga  Aug 12  Comment 
Exact Sciences (NASDAQ: EXAS) shares moved up 6.21% to $18.15. The volume of Exact Sciences shares traded was 2588% higher than normal. Exact Sciences announced the FDA approval of Cologuard. Intercept Pharmaceuticals (NASDAQ: ICPT) surged...
newratings.com  Aug 12  Comment 
BEIJING (dpa-AFX) - Chinese medical device maker Mindray Medical International Ltd. (MR) reported Monday a profit for the second quarter that declined four percent from last year, despite revenue growth, reflecting lower operating margins amid...
newratings.com  Aug 11  Comment 
WASHINGTON (dpa-AFX) - Mindray Medical International Limited (MR) reported that its second-quarter net income decreased to $59.6 million or $0.50 per share from $62.1 million or $0.51 per share, last year. Non-GAAP earnings per share was 0.56, for...





 
TOP CONTRIBUTORS
Mindray Medical International Limited engages in the development, manufacture, and marketing of medical devices in China.

Business Overview

It offers approximately 40 products through its three segments: Patient Monitoring Devices, Diagnostic Laboratory Instruments, and Ultrasound Imaging Systems. The company's Patient Monitoring Devices segment primarily offers portable PM-9000 multi-parameter patient monitoring device and approximately 15 patient monitoring devices. The Diagnostic Laboratory Instruments segment offers a range of approximately 10 hematology and biochemistry analyzers that perform analysis on blood, urine, and other bodily fluid samples for clinical diagnosis and treatment. The Ultrasound Imaging Systems segment offers approximately 10 ultrasound imaging systems and it would introduce the color Doppler ultrasound imaging system for use in several clinical areas, such as urology, gynecology, obstetrics, and cardiology. The company sells its products primarily to distributors and directly to hospitals, clinics, government agencies, original design manufacturers, and original equipment manufacturers. It also offers its products in Asia and Europe. In addition, the company designs and develops equipment to customers? specifications. Mindray Medical International was incorporated in 2005 and is headquartered in Shenzhen, the People?s Republic of China.

The three segments made up one-third of the revenue last year. However, the growth in each division varies. Patient monitoring and life support showed growth of 30.2% over last year. However, In-Vitro diagnostic products saw 56.1% growth and the Medical Imaging division was up over 61%. The company received FDA approval for an additional 3 products during the quarter which expands their offering suite to the US. As of the end of the quarter, Mindray now has developed and manufactures over 40 products which are available in more than 140 countries.

Financials

Mindray Medical International Limited (MR) reported earnings earlier in 2008. After a tumultuous decline late in the first quarter, the stock had begun to rebound, and then moved decidedly higher on the announcement. Revenue came in at $89.3 million which was good for a 48.2% increase. More importantly, the company’s international revenue (outside its home country of China) was $45.6 million or 49.4% higher. Since management has continued to reaffirm its commitment to growing outside its primary China market, it was encouraging to see international sales make up more than half of total revenue. The company continues to enjoy a healthy 57% gross margin and net income came in at $28.4 million or 25 cents per share. Management noted its pride in the fact that the bottom line is actually growing more quickly than the revenue numbers, indicating strong operating leverage.

Trends and Forces

Changes in the the Tax Rate

China’s tax rate is undergoing transition and moving towards a flat 25% rate for most firms. There is an exception for “new and hi-tech enterprises” which would lower the tax rate to 15%. At this point, Mindray has failed to secure the designation and so the accounting takes into account a transition over the next 5 years to the new 25% rate. It may turn out that the company will be able to fall under the preferential treatment and if this happens, the additional tax paid will likely be deducted from future liabilities. However, this is not a guarantee and the higher tax rate would definitely be an incremental detriment to profits.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki